Ticagrelor Ticagrelor Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y receptor. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high
Chlorosulfuric acid Chlorosulfuric acid Chlorosulfuric acid (IUPAC name: sulfurochloridic acid) is the inorganic compound with the formula HSOCl. It is also known as chlorosulfonic acid, being the sulfonic acid of chlorine. It is a distillable, colorless liquid which is hygroscopic and a powerful lachrymator. Salts and esters of chlorosulfuric acid are known as chlorosulfates. Chlorosulfuric acid is a tetrahedral molecule. The formula is more descriptively written SO(OH)Cl, but HSOCl is traditional. It is an intermediate, chemically and conceptually, between sulfuryl chloride (SOCl) and sulfuric acid (HSO). The compound is rarely obtained pure. Upon standing with excess sulfur trioxide, it decomposes to pyrosulfuryl